Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329

Benzinga Newsdesk www.benzinga.com Negative 91.2%

Neg 91.2% Neu 0% Pos 0%

Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.